1. Adelaide Research & Scholarship

Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 15 (Search time: 0.004 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2009Pancreatic cancer epidemiology and survival in an Australian populationLuke, C.; Price, T.; Karapetis, C.; Singhal, N.; Roder, D.
2007Cetuximab for the treatment of colorectal cancerJonker, D.; O'Callaghan, C.; Karapetis, C.; Zalcberg, J.; Tu, D.; Au, H.; Berry, S.; Krahn, M.; Price, T.; Simes, R.; Tebbutt, N.; van Hazel, G.; Wierzbicki, R.; Langer, C.; Moore, M.
2013The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumorsRosen, L.; Lipton, L.; Price, T.; Belman, N.; Boccia, R.; Hurwitz, H.; Stephenson Jr, J.; Wirth, L.; McCoy, S.; Hei, Y.; Hsu, C.; Tebbutt, N.
2013Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapyPadman, S.; Padbury, R.; Beeke, C.; Karapetis, C.; Bishnoi, S.; Townsend, A.; Maddern, G.; Price, T.
2012Impact of age on choice of chemotherapy and outcome in advanced colorectal cancerKhattak, M.; Townsend, A.; Beeke, C.; Karapetis, C.; Luke, C.; Padbury, R.; Maddern, G.; Roder, D.; Price, T.
2007Treatment and survival from breast cancer: The experience of patients at South Australian teaching hospitals between 1977 and 2003Luke, C.; Gill, P.; Birrell, S.; Humeniuk, V.; Borg, M.; Karapetis, C.; Koczwara, B.; Olver, I.; Penniment, M.; Pittman, K.; Price, T.; Walsh, D.; Yeoh, E.; Roder, D.
2013Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17Vickers, M.; Karapetis, C.; Tu, D.; O'Callaghan, C.; Price, T.; Tebbutt, N.; van Hazel, G.; Shapiro, J.; Pavlakis, N.; Gibbs, P.; Blondal, J.; Lee, U.; Meharchand, J.; Burkes, R.; Rubin, S.; Simes, J.; Zalcberg, J.; Moore, M.; Zhu, L.; Jonker, D.
2008K-ras mutations and benefit from cetuximab in advanced colorectal cancerKarapetis, C.; Khambata-Ford, S.; Jonker, D.; O'Callaghan, C.; Tu, D.; Tebbutt, N.; Simes, R.; Chalchal, H.; Shapiro, J.; Robitaille, S.; Price, T.; Shepherd, L.; Au, H.; Langer, C.; Moore, M.; Zalcberg, J.
2008Exploring the epidemiological characteristics of cancers of unknown primary site in an Australian population: implications for research and clinical careLuke, C.; Koczwara, B.; Karapetis, C.; Pittman, K.; Price, T.; Kotasek, D.; Beckmann, K.; Brown, M.; Roder, D.
2010Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancerPeeters, M.; Price, T.; Cervantes, A.; Sobrero, A.; Ducreux, M.; Hotko, Y.; Andre, T.; Chan, E.; Lordick, F.; Punt, C.; Strickland, A.; Wilson, G.; Ciuleanu, T.; Roman, L.; Van Cutsem, E.; Tzekova, V.; Collins, S.; Oliner, K.; Rong, A.; Gansert, J.

Discover